Background {#Sec1}
==========

Attention Deficit Hyperactivity Disorder (ADHD), the most common neurobehavioral disorder in children \[[@CR1], [@CR2]\], is associated with significant impairments in academic, social, and occupational functioning \[[@CR3]\]. ADHD is a heritable disorder, but environmental and other modifiable risk factors have also been implicated \[[@CR4]\]. The link between ADHD and environmental toxins, including organophosphate pesticides, is growing \[[@CR5]--[@CR7]\]. Due to increasing concern about their adverse health consequences, the U.S. Environmental Protection Agency banned the two most commonly used organophosphate pesticides from residential use in 2000--2001, leading to escalating use of an alternative class of pesticides \-- the pyrethroids \[[@CR8]\]. Pyrethroids are now the most commonly used pesticides for residential pest control and public health purposes (including control of vector-borne diseases) \[[@CR8]\], and are also increasingly used in agriculture \[[@CR9], [@CR10]\], with U.S. biomonitoring studies confirming widespread exposure to one or more pyrethroids \[[@CR11]\].

Although pyrethroid pesticides are often considered a "safer" choice because they are generally not as acutely toxic as organophosphates \[[@CR12]\], animal studies indicate that exposure to pyrethroids may not be benign. Specifically, increased dopamine transporter (DAT) expression \[[@CR13]\] and elevated DAT-mediated dopamine uptake \[[@CR14], [@CR15]\] were detected in mice exposed to the pyrethroids deltamethrin and permethrin. Given that elevated DAT expression has been observed in some studies of individuals with ADHD \[[@CR16]\] and that a dopamine deficit has been hypothesized to be central to the neurophysiology of ADHD \[[@CR17]\], it is plausible that pyrethroid exposure could elevate the risk for developing ADHD. Indeed, numerous studies have found that rodents exposed to pyrethroids during a critical period of brain development have increased locomotor activity during adulthood \[[@CR18]--[@CR23]\]. In addition, this animal research indicates that there may be a heightened vulnerability to the effects of pyrethroid exposure on hyperactivity, impulsivity, and dopamine transporter levels in male compared to female mice \[[@CR23], [@CR24]\].

In prior publications, the behavioral effects of pyrethroid exposure in children have received little attention. Oulhote *et al*. found that postnatal pyrethroid exposure was associated with general behavioral difficulties \[[@CR25]\], but, contrary to the animal study findings, this association was more pronounced in girls compared to boys. \[[@CR25]\] Quiros-Alcala *et al*. did not observe a significant relationship between current pyrethroid exposure and *parent report* of a prior ADHD diagnosis \[[@CR26]\]. However, no previous publications have utilized an ADHD-specific diagnostic measure or examined ADHD symptoms dimensionally when evaluating the association between pyrethroid biomarkers and ADHD.

We hypothesized that current pyrethroid pesticide exposure would be associated with a positive ADHD diagnostic status and an increased number of ADHD symptoms in a nationally representative sample of U.S. children when ascertainment included an ADHD-specific diagnostic measure. In addition, we sought to test whether the effects of pyrethroids differed in boys compared to girls, given that human and animal studies indicate contrasting sex-specific effects.

Methods {#Sec2}
=======

Study participants {#Sec3}
------------------

Our study sample consisted of subjects that participated in the National Health and Nutrition Examination Survey (NHANES). The NHANES is a multi-stage probability sample survey that assesses the health and nutritional status of the US population. We used data from NHANES 2001--2002 for 8 to 15 year old children, which was the only NHANES cycle that included a structured diagnostic interview of children's ADHD symptoms, concurrent pyrethroid pesticide biomarkers, and relevant covariates \[[@CR27]\]. Pyrethroid pesticide exposure measurements were collected in a random sample of 50 % of the 8 to 11 year olds and 33 % of the 12 to 15 year olds who participated in the 2001--2002 data collection. Data from the diagnostic interview of ADHD symptoms was available for 84 % of children. Of the 2,028 8 to 15 year old children participating in the NHANES, data from 687 children (34 % of total) was available for these analyses. Children who were included in these analyses did not differ from children who were not included on age, sex, race/ethnicity, income, health insurance status, prenatal tobacco exposure, birth weight, current tobacco exposure, blood lead level, urinary organophosphate metabolite levels, caregiver report of a prior ADHD diagnosis, ADHD diagnostic status as determined by DSM-IV criteria, or ADHD defined by caregiver report and/or DSM-IV criteria (See Table [1](#Tab1){ref-type="table"}).Table 1Comparison of characteristics for participants age 8-15 years not included and included in sampleNot IncludedIncludedCharacteristicN with Characteristic^a^%^a^Overall N^a^N with Characteristic^a^%^a^Overall N^a^Age 8-11 years49046.8134130746.5687Male gender66151.3134132352.9687Race/ethnicity  African American45115.4134121013.0687  Mexican American38611.0134120511.1687  Other race/ethnicity11114.213415612.5687White, non-Hispanic39359.4134121663.4687Caregiver report of ADHD969.711396610.8684DSM-IV Defined ADHD759.9966559.6667ADHD by DSM-IV Criteria and/or Caregiver report13717.89809314.6687Poverty-Income Ratio  \<1.0037020.9126020320.7664  1.00-1.8531822.7126015520.2664  \>1.85-3.0023120.0126012522.0664  \>3.0034136.4126018137.1664Reported health insurance110988.0132556483.6681Reported prenatal tobacco exposure20317.213259218.1677Birth weight \<2.5 kg1308.21322505.9682Reported current household tobacco smoke exposure29823.2132614522.7683Urinary 3-PBA \< LOD2923.214813121.2687*Abbreviations*: ADHD, Attention-Deficit/Hyperactivity Disorder; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; SE, standard error; LOD, limit of detection; 3-PBA, 3-phenoxybenzoic acid^a^N reflects actual sample size, % is weighted to reflect national prevalence estimates

ADHD measurement {#Sec4}
----------------

Our primary outcome was ADHD, defined as meeting DSM-IV criteria for ADHD and/or having a caregiver-reported prior diagnosis of ADHD. The National Institute of Mental Health Diagnostic Interview Schedule for Children (DISC) was used to assess for DSM-IV-defined ADHD based on standardized algorithms as per prior studies \[[@CR1]\]. The DISC is a structured diagnostic interview instrument designed for use in epidemiological and clinical studies, with reliable versions available in English \[[@CR28]\] and Spanish \[[@CR29], [@CR30]\]. Caregivers completed the ADHD DISC module two to four weeks after the child's NHANES Mobile Examination Center evaluation, providing information about the child's ADHD symptoms, age of onset, symptom pervasiveness, and related impairments over the prior twelve months. In our sample, participants' Inattentive symptom counts had a mean (SD) = 1.3 (2.4), median = 0, and range = 0-9; Hyperactive-Impulsive symptom counts had a mean (SD) = 1.0 (2.0), median = 0, and range = 0-9. Given that over half of children diagnosed with ADHD during earlier childhood continue to have significant impairment but no longer meet formal diagnostic criteria during adolescence \[[@CR31], [@CR32]\], and that successful treatment with ADHD medications can reduce symptoms below the diagnostic threshold, our primary ADHD case definition also included prior caregiver report of an ADHD diagnosis. To determine whether a child had a prior ADHD diagnosis, caregivers were asked, "Has a doctor or health professional ever told you that \[child's name\] had attention deficit disorder?" during an NHANES interview module that occurred before the DISC interview.

Pyrethroid pesticide exposure biomarker {#Sec5}
---------------------------------------

Our primary exposure was urinary levels of 3-phenoxybenzoic acid (3-PBA). 3-PBA is a metabolite of several pyrethroid pesticides, and is the most frequently detected pyrethroid metabolite in studies of children that assess pyrethroid exposure from multiple sources (including food and within the home) \[[@CR11]\]. Urinary measures of 3-PBA were determined using high-performance liquid chromatography/electrospray chemical ionization/tandem mass spectrometry \[[@CR27], [@CR33]\]. The limit of detection for 3-PBA was 0.1 μg/l.

Covariates {#Sec6}
----------

We included potential confounders that might bias the association between pyrethroid pesticide biomarkers and ADHD in the statistical models. These were chosen based on their association with ADHD in the prior literature, and included child sex \[[@CR34]\], household income to poverty line ratio \[PIR\] (in quintiles) \[[@CR1]\], age \[[@CR34]\], race/ethnicity (African-American, Mexican-American, Non-Hispanic white, or Other race) \[[@CR1]\], health insurance status (yes or no) \[[@CR35]\], prenatal tobacco exposure (yes or no) \[[@CR36], [@CR37]\], blood lead level \[[@CR36], [@CR37]\] (log~10~-transformed), and urinary organophosphate pesticide metabolite level \[[@CR6]\] (3 dimethyl alkylphosphate \[DMAP\], log~10~-transformed). Race was identified by the caregiver. The Other race category (N = 56) included both non-Mexican Hispanic individuals as well as those individuals who identified as "other race" because of the small number of participants identified in either group. Health insurance status was reported by the caregivers. Models were also adjusted for urinary creatinine levels (as recommended by Barr *et al*. \[[@CR38]\]) to account for urine dilution.

Analyses {#Sec7}
--------

This study was determined to be exempt from review by the institutional review board (IRB) at Cincinnati Children's Hospital Medical Center (Study **\#**: 2011-1686). Descriptive statistics on the prevalence of ADHD \[DSM-IV-defined ADHD and/or reported prior diagnosis\] were tabulated for those who had urinary 3-PBA levels below and above the limit of detection.

The association between ADHD and urinary 3-PBA (levels below versus above the limit of detection) was analyzed via logistic regression, adjusting for potential confounders. Logistic regression was used to examine the association between continuous urinary 3-PBA levels (log~10~-transformed due to skewed distributions) and ADHD, adjusting for potential confounders. To examine the consistency of pyrethroid pesticide associations, additional analyses, available in Additional file [1](#MOESM1){ref-type="media"}: Table S1 and Additional file [2](#MOESM2){ref-type="media"}: Table S2, were conducted to examine associations with the individual components of our ADHD case definition separately \[i.e., 1) meeting DSM-IV criteria for ADHD, 2) having a caregiver report of a prior ADHD diagnosis\] but are less precise due to smaller cell sizes.

We used Poisson regression to assess the relationship between urinary 3-PBA levels and the number of inattentive and hyperactive symptoms endorsed as being present 'often' in at least two settings, adjusting for potential confounders. The Poisson distribution accounts for the skewed and count nature of these data. Analyses investigated urinary 3-PBA levels as both a dichotomous predictor (levels below versus above the limit of detection) and a continuous predictor (log~10~-transformed levels). For each model, adjusted count ratios were calculated to determine the mean percent increase in symptom counts beyond that of the reference group for each stratum of the 3-PBA variables.

To examine the dose--response relationship between continuous 3-PBA levels and ADHD, we fit 3-knot restricted cubic polynomial splines (with knots at the 10^th^, 50^th^, and 90^th^ percentiles of log~10~-transformed urinary 3-PBA levels), adjusting for potential confounders. Analyses using restricted cubic polynomial splines provide flexibility in modeling the relationship between the exposure and the outcome, and avoid assumptions about model linearity \[[@CR39]\].

Finally, due to evidence that the neurobehavioral effects of pyrethroid pesticide exposure may differ in males and females, we conducted stratified analyses by child gender and formally tested effect measure modification using a sex\*3-PBA interaction term in our logistic regression models.

Analyses were performed using SUDAAN (version 9, Research Triangle Institute, Research Triangle Park, NC) to account for NHANES' complex survey design. Sample weights were applied according to National Center for Health Statistics guidelines to generate all estimates.

Results {#Sec8}
=======

Descriptive statistics {#Sec9}
----------------------

Among 8 to 15 year old participants (n = 687), 14.6 % (95 % CI, 10.6-19.8) met our primary ADHD definition: meeting DSM-IV criteria for ADHD and/or having a prior ADHD diagnosis. Table [1](#Tab1){ref-type="table"} lists separate rates of participants 1) meeting DSM-IV criteria for ADHD and 2) having a prior reported ADHD diagnosis. The weighted mean urinary 3-PBA level in our sample was 1.14 μg/L (Standard Error ±0.22), and the 10^th^, 50^th^, and 90^th^ percentiles were 0.07, 0.29, and 1.94 μg/L respectively. Urinary 3-PBA levels were below the limit of detection (LOD) in 21.1 % (N = 131) of participants.

Associations between pyrethroid pesticides on ADHD {#Sec10}
--------------------------------------------------

In bivariate analyses, the prevalence of ADHD was higher in those who had detectable urinary pyrethroid pesticide levels than in those with non-detectable levels (16.0 % vs 9.6 %, *p* = 0.03). After confounder adjustment, children who had detectable urinary 3-PBA levels were more than twice as likely to have ADHD compared with those who had non-detectable levels (adjusted odds ratio \[aOR\] 2.42; 95 % confidence interval \[CI\] 1.06, 5.57). Each 10-fold increase in urinary 3-PBA level (corresponding approximately to a shift of 3-PBA levels from the 20^th^ to 80^th^ percentile) was associated with a 57 % increase in the prevalence of ADHD (aOR 1.57; 95 % CI 0.88, 2.78).

In sex-stratified analyses, we found stronger associations between urinary 3-PBA levels and ADHD in boys compared to girls. Boys with detectable urinary 3-PBA levels were almost three times as likely to have ADHD compared with boys who had non-detectable levels (aOR 2.95; 95 % CI 1.07, 8.08), while the effects of 3-PBA levels in girls were smaller (aOR for girls with detectable vs non-detectable levels: 1.54; 95 % CI 0.32, 7.33). However, the effect modification (3-PBA\*sex interaction term) p-value was not statistically significant (*p* = 0.68). Modeling urinary 3-PBA levels as a logarithmically-transformed continuous variable was more suggestive of sex-specific effects (3-PBA\*sex interaction term *p* = 0.09). For boys, a 10-fold increase in urinary 3-PBA level was associated with a 43 % increase in the prevalence of having either DSM-IV-defined or parent-reported ADHD (aOR 1.43; 95 % CI 1.05, 1.94), while for girls this association was null (aOR 0.91; 95 % CI 0.57, 1.43).

Associations between pyrethroid pesticides and ADHD symptom counts {#Sec11}
------------------------------------------------------------------

Higher 3-PBA levels were associated with an increasing number of hyperactive-impulsive symptoms. Hyperactive-impulsive symptom counts were 77 % higher for children with detectable 3-PBA levels compared to children with non-detectable levels (adjusted count ratio \[aCR\] 1.77; 95 % CI 0.95, 3.30) (Table [2](#Tab2){ref-type="table"}). A similar relationship was observed when 3-PBA levels were modeled as a continuous log~10~-transformed variable: every 10-fold increase in urinary 3-PBA levels was associated with a 50 % increase in hyperactive-impulsive symptoms (aCR 1.50; 95 % CI 1.03, 2.19). No significant or borderline significant associations were observed between inattentive symptom counts and 3-PBA levels (modeled as either a dichotomous or continuous variable) in whole sample models (Table [2](#Tab2){ref-type="table"}).Table 2Adjusted count ratios^a^ for association of urinary 3-PBA levels with inattentive and hyperactive-impulsive symptom countsInattentive Symptom CountHyperactive-Impulsive Symptom CountACR (95 % CI)ACR (95 % CI)Urinary 3-PBA Level ≥ LOD  Overall1.26 (0.75, 2.12)1.77 (0.95, 3.30)  Boys1.61 (0.92, 2.80)2.49 (1.17, 5.27)  Girls0.89 (0.44, 1.81)1.01 (0.51, 2.00)Log~10~-transformed Urinary 3-PBA  Overall1.21 (0.83, 1.78)1.50 (1.03, 2.19)  Boys1.49 (1.05, 2.12)1.57 (1.05, 2.34)  Girls1.00 (0.58, 1.71)1.51 (0.88, 2.60)*Abbreviations*: 3-PBA, 3-phenoxybenzoic acid; ACR, Adjusted Count Ratios; LOD, limit of detection^a^Adjusted for child's age, race/ethnicity, income, health insurance status, prenatal tobacco exposure, blood lead level (log~10~-transformed), urinary organophosphate metabolite level (log~10~-transformed), and urinary creatinine level. Overall models also adjust for sex

Sex-stratified analyses revealed significant associations between 3-PBA levels and ADHD symptom counts in boys but not girls (Table [2](#Tab2){ref-type="table"}). Hyperactive-impulsive symptoms were more than double in boys with detectable urinary 3-PBA levels compared to those with non-detectable levels (aCR 2.49; 95 % CI 1.17, 5.27). When 3-PBA levels were modeled as a log~10~-transformed continuous variable, each 10-fold increase in urinary 3-PBA levels was associated with a 49 % increase in inattentive symptom counts (aCR 1.49; 95 % CI 1.05, 2.12) and a 57 % increase in hyperactive-impulsive symptom counts (aCR 1.57; 95 % CI 1.05, 2.34) among boys.

Spline analyses {#Sec12}
---------------

Our restricted cubic polynomial spline analysis in the overall sample suggested a steeper increase in the log-odds of ADHD at the lower 3-PBA levels, with the association between the log-odds of ADHD and pyrethroid metabolite levels remaining elevated but plateauing at higher 3-PBA levels (Fig. [1](#Fig1){ref-type="fig"}). Sex-stratified spline analyses demonstrated sex-specific effects of pyrethroid exposure. In boys, a curvilinear dose--response relationship was observed between 3-PBA levels and increasing log-odds of ADHD with no plateau level observed (Fig. [2](#Fig2){ref-type="fig"}). Spline analysis in girls revealed a relatively flat relationship between 3-PBA exposure levels and ADHD such that increasing pyrethroid metabolite levels did not appreciably increase log-odds of ADHD (Fig. [3](#Fig3){ref-type="fig"}). The likelihood ratio test for all 3 splines (overall sample, boys only, and girls only) had *p* \< 0.01, indicating goodness of fit for all three models.Fig. 1Spline Analysis^1^ Depicting Association Between 3-PBA Levels (on a Log~10~ Scale) and Odds of ADHD^2^ in Overall Sample. Figure Legend: ^1^Adjusted for child's age, sex, race/ethnicity, income, health insurance status, prenatal tobacco exposure, blood lead level (log~10~-transformed), urinary organophosphate metabolite level (log~10~-transformed), and urinary creatinine level. ^2^Met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)-criteria for ADHD and/or had caregiver report of a prior ADHD diagnosis. Abbreviations: ADHD, Attention-Deficit/Hyperactivity Disorder; 3-PBA, 3-phenoxybenzoic acidFig. 2Spline Analysis^1^ Depicting Association Between 3-PBA Levels (on a Log~10~ Scale) and Odds of ADHD^2^ in Boys. Figure Legend: ^1^Adjusted for child's age, race/ethnicity, income, health insurance status, prenatal tobacco exposure, blood lead level (log~10~-transformed), urinary organophosphate metabolite level (log~10~-transformed), and urinary creatinine level. ^2^Met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)-criteria for ADHD and/or had caregiver report of a prior ADHD diagnosis. Abbreviations: ADHD, Attention-Deficit/Hyperactivity Disorder; 3-PBA, 3-phenoxybenzoic acidFig. 3Spline Analysis^1^ Depicting Association Between 3-PBA Levels (on a Log~10~ Scale) and Odds of ADHD^2^ in Girls. Figure Legend: ^1^Adjusted for child's age, race/ethnicity, income, health insurance status, prenatal tobacco exposure, blood lead level (log~10~-transformed), urinary organophosphate metabolite level (log~10~-transformed), and urinary creatinine level. ^2^Met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)-criteria for ADHD and/or had caregiver report of a prior ADHD diagnosis. Abbreviations: ADHD, Attention-Deficit/Hyperactivity Disorder; 3-PBA, 3-phenoxybenzoic acid

Discussion {#Sec13}
==========

Higher pyrethroid exposure was associated with an elevated odds of ADHD and ADHD symptoms in this nationally representative sample of US children. Our results are consistent with the findings in animal models \[[@CR21]--[@CR24]\], but contrast with a study by Quiros-Alcala *et al*. which also used an NHANES sample but did not find pyrethroid exposure to be significantly associated with ADHD \[[@CR26]\]. This contrasting result may be due to differences in the primary outcome definition. The Quiros-Alcala *et al*. study's primary outcomes were based on parental report of ADHD and/or parental report of a learning disability; they did not incorporate diagnosis of ADHD or ADHD symptom counts as determined by the DISC, which may represent more sensitive measures. Additional differences between the Quiros-Alcala *et al*. study and the present study include the age range (6--15 vs. 8--15 year old) and NHANES study years (1999--2002 vs. 2001--2002). Another prior study in children found an association between postnatal pyrethroid exposure and a general parent-report measure of behavior problems, but did not find a specific association with hyperactivity/inattention \[[@CR25]\], perhaps due to the diminished sensitivity of their 5-item ADHD symptom measure (compared to our DSM-IV-based measure of 18 symptoms).

Our results suggest that pyrethroid pesticide exposure may be more strongly associated with hyperactive-impulsive than inattentive symptoms. This is consistent with previous animal studies demonstrating that pyrethroid exposure during gestation and early childhood results in hyperactivity and impulsive-like behavior \[[@CR19], [@CR23]\]. Should the link between pyrethroid exposure and hyperactivity-impulsivity in children be replicated, these findings might represent a potential pyrethroid-specific ADHD phenotype. Efforts to characterize etiologic-specific ADHD phenotypes are paramount not only to elucidating the biologic basis of ADHD: they may ultimately prove useful in defining subgroups of children with ADHD with a distinct course, comorbidity profile, and intervention response, and thus form the basis for targeted clinical and treatment efforts \[[@CR4]\].

We observed sex-specific effects of pyrethroid exposure. Urinary pyrethroid biomarkers were associated with increased odds of an ADHD diagnosis and number of ADHD symptoms for boys but not girls in logistic and poisson regression as well as spline analyses. The sex\*pyrethroid interaction had a borderline significant p-value of 0.09 when 3-PBA was modeled as a logarithmically-transformed continuous variable. In contrast, the interaction was not statistically significant (*p* = 0.68) when 3-PBA was modeled as a dichotomous variable \[above versus below the limit of detection\]). Of note, we had reduced statistical power to detect sex\*pyrethroid interactions in dichotomous models due to relatively small numbers of participants having the ADHD diagnosis. This pattern suggesting possible sex-specific effects is consistent with prior animal studies that reported greater impulsive and hyperactive symptoms in exposed male but not female mice \[[@CR23], [@CR24]\]. Further, these animal studies suggest that male-specific effects of pyrethroid exposure on the brain dopamine system underlie the observed sexual dimorphism in behavioral effects \[[@CR23], [@CR24]\]. It should be noted that Oulhote *et al*. found a stronger adverse association between pyrethroid exposure and a measure of total behavioral difficulties as well as oppositional/conduct-specific problems in girls compared to boys \[[@CR25]\], although the contrast between their findings and our own is not direct given that the sex-specific effects were observed on different outcomes. Quiros-Alcala *et al*. did not find any significant interactions (all *p* \> 0.10) between sex and pyrethroid exposure, and it is not clear if they observed any patterns suggesting possible sex-specific effects despite the failure to meet thresholds for statistical significance. Certainly, further study of sex-specific vulnerability to pyrethroid exposure is warranted, given mounting evidence that the adverse effects of some ADHD risk factors may be accentuated or limited to certain groups \[[@CR40]\].

Strengths of this study included our use of a nationally representative sample of the U.S. population, such that pyrethroid exposure levels are more likely to represent the experience of a broad range of American children and adolescents compared to regionally based studies. In addition, our use of both linear and spline models allowed us to explore more carefully the dose--response relationship between childhood pyrethroid metabolite levels and ADHD. Our exploration of the relationship between pyrethroid levels and ADHD symptom counts -- in addition to ADHD diagnostic status \-- also enable a fuller appreciation of the unique ADHD sub-domains that might be more affected by pyrethroid exposure. However, it should be noted that our Poisson models show some evidence of over-dispersion and therefore significance may be overestimated.

An additional limitation of our study is that pyrethroid exposure was assessed using 3-PBA concentrations in a single spot urine sample. Given that pyrethroids are non-persistent and rapidly metabolized, serial measurements would provide a more accurate measurement of typical exposure \[[@CR41]\], and are recommended in future studies. It should also be noted that 3-PBA detected in child urine may not be due entirely to exposure to parent pyrethroid compounds, as there may also be a minor contribution from exposure to a byproduct formed after pyrethroids have been hydrolyzed in the environment. Thus, we expect that some degree of exposure misclassification occurred in this study; if it is non-differential in nature, the *tendency* would be to bias toward the null, making results an under-, rather than overestimate of the true association \[[@CR42], [@CR43]\]. Subsequent studies should also examine the association between measures of *prenatal* pyrethroid exposure (which are not available in NHANES) and later development of ADHD, as data from animal studies suggest that both the prenatal and postnatal periods may represent susceptible phases for pyrethroid neurotoxicity \[[@CR18]--[@CR23]\]. Another caveat to our study is that we categorized urinary pyrethroid concentrations using the LOD as a cut point because the LOD represents an easily interpretable threshold. However, to guard against the assumption of constant effect sizes without our categories, we also conducted analyses using a restricted cubic polynomial spline, which makes no assumptions about the shape of the dose--response relationship (see Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}).

Misclassification of ADHD may also have played a role in analyses for which case ascertainment included caregiver report of the child's prior diagnosis of ADHD, as we cannot verify that doctors in community-based settings used DSM-IV criteria when establishing ADHD diagnoses \[[@CR44]\]. However, our results were similar in direction and magnitude when ADHD diagnosis was based on the standardized, valid, and reliable DISC instrument (see Additional file [1](#MOESM1){ref-type="media"}: Table S1), although the findings were less precise (likely due to a reduction in cell size for this outcome), and the DISC is a caregiver-completed measure that does not incorporate teacher reports of ADHD symptoms. Furthermore, we caution that correlation does not prove causation in this cross-sectional study. Although we adjusted for a number of potential confounders, we were unable to control for genetic and other factors (e.g., diet, other aspects of the caregiving environment) that may account for the observed associations and could in fact represent reverse causality. Nonetheless, prospective animal studies in which case and control subjects had identical genetic lineages and rearing environments, but differed only in the pesticide exposure, document pyrethroid effects on hyperactivity and impulsivity \[[@CR18]--[@CR23]\] that corroborate our findings.

Conclusions {#Sec14}
===========

Our results suggest an association between childhood urinary pyrethroid pesticide biomarkers and ADHD, particularly hyperactive-impulsive symptoms, and these associations may be stronger in boys than girls. Given the growing use of pyrethroid pesticides and the perception that they represent a safer pesticide alternative, these results may be of considerable public health importance. However, replication of findings is warranted in prospective, longitudinal studies with serial measurements of pyrethroid pesticide exposure.

Additional files {#Sec15}
================

Additional file 1: Table S1.Adjusted Odds Ratios^1^ of DSM-IV-Defined ADHD and Caregiver-Reported ADHD by Urinary 3-PBA Status. Table shows adjusted odds ratio of DSM-IV-defined ADHD separately from adjusted odds ratio of caregiver-reported ADHD by urinary 3-PBA status (above versus below the limit of detection).Additional file 2: Table S2.Adjusted Odds Ratios of DSM-IV-Defined ADHD and Caregiver-Reported ADHD for every 10-fold Increase in Urinary 3-PBA Levels. Table shows adjusted odds ratio of DSM-IV-defined ADHD separately from adjusted odds ratio of caregiver-reported ADHD for every 10-fold increase in urinary 3-PBA levels.
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